| Company | Introduction |
| Fujian Akeylink Biotechnology | Akeylink is an innovative drug R&D subsidiary held by Cosunter Cosunter Pharmaceutical is a company focusing on the R&D and manufature of anti-HBV (hepatitis B virus) drugs. Founded in June 2001, it has now developed into a leading modern pharmaceutical company with annual sales of over RMB 500 million yuan. All production lines of the company passed the revised GMP certification in August 2014. |
| 广生中霖 | 广生中霖是福建广生堂药业股份有限公司控股的创新药物研发子公司，福建广生堂药业股份有限公司是一家专注于抗HBV（乙型肝炎病毒）药物研发和生产的公司。公司成立于2001年6月，现已发展成为一家年销售额超过5亿元人民币的领先现代制药公司。公司所有生产线于2014年8月通过修订后的GMP认证。 |
| Elixiron Immunotherapeutics | Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. |
| 安立玺荣 | 安立玺荣生物医药是一家专注于创新型免疫治疗的新药研发公司。公司拥有全球领先的自主研发平台，开发针对肿瘤，神经系统疾病和免疫性疾病的BIC/FIC（Best/First In Class）创新性免疫疗法。 |
| SciMount Therapeutics | SciMount Therapeutics is a wholly owned subsidiary of Chengdu Xilingyuan Pharmaceutical Co., Ltd. dedicated to the development of innovative drugs for the treatment of gastrointestinal (GI) diseases and cancer, with operations in China, the United States and Australia. Kelingyuan has established a team of internationally advanced professionals and top academic consultants, with innovative drug product pipeline in multiple stages of development. |
| 科岭源 | 成都科岭源医药技术有限公司致力于开发治疗胃肠道（GI）疾病和癌症的创新药物，业务分布于中国、美国和澳大利亚。科岭源已组建了一支具有国际先进水平的专业人才团队及顶尖的学术顾问团队，拥有多个研发阶段的创新药产品管线。 |
| ImmuneOnco | Established in 2015,ImmuneOnco is an early-stage biopharma company dedicated to the development to commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells. Their lead asset SIRPa-Fc fusion protein which works by inhibiting CD47, and its Phase 1 study has been completed. Recently, they closed their Series C financing round and received 89 million USD from well-known funds, the main investors include Greater Bay Area Homeland Investments, Lily Aisa Ventures and LYFE Capital. |
| 宜明昂科 | 宜明昂科生物医药技术（上海）有限公司创立于2015年6月，注册地为上海张江高科技园区。公司主要致力于肿瘤免疫治疗产品开发研究，主要包括双特异性抗体、新型重组蛋白、以及TANKTM 细胞治疗等。这些产品的共同特征就是通过激发调动患者自身的免疫系统来发挥抗肿瘤效应，并最终抑制肿瘤细胞的继续生长，逆转由此而导致的一系列恶性症状，从而让患者逐渐回到健康的机体状态。 |
| Immunophage | Established in 2016,Immunophage focuses on immune regulation, discovering new targets and signaling pathways to precisely regulate the immune system, and providing the potentially best treatment options for malignant tumor, autoimmune diseases, neurodegenerative diseases and metabolic diseases. The founder was previously served in world-renewed research institutions as tenured faculty and MNCs and has over 28 years of research experience in drug development. All the assets under development are first-in-class and have filed new chemical structure or new antibody structure patents. The company has a robust pipeline with twelve first-in-class assets in the clinical and preclinical stage. Their lead assets that target MIF and CCR8 are the most advanced in clinical development. The company is expected to file more than seven new INDs by the end of 2022. |
| 艾美斐 | 成立于2016年，艾美斐是一家专注于开发用于治疗恶性肿瘤、自身免疫性疾病、代谢性疾病和神经退行性疾病等疾病的创新药研发公司。公司所有在研产品均为自研First-in-class药物，具有全新的抗体结构或全新的化合物结构。其中2个创新靶点为全球首家/唯一获批临床的产品。此外，公司后续管线强劲，有10余项临床前在研管线，预计至2022年底再完成7项以上新IND资料提交。创始人在该领域拥有近30年研究开发经验，包括在Big pharma领导参与多个上市新药的开发。 |
| YZY Bio | YZY biopharma is a leading biopharmaceutical R&D company founded in 2010 with a proprietary, unique and efficient technique platform called Ybody® that generates bispecific molecules. The company is equipped with full functional R&D center and pilot production Lines based in Wuhan. A cGMP commercial scale production facility is under construction. |
| 友芝友生物制药 | 武汉友芝友生物制药有限公司是一家专门从事以免疫和靶向疗法为核心的生物制药公司，专注于双特异性抗体药物的研发与产业化。双特异性抗体药物是下一代抗体药物的核心研发方向，在肿瘤、免疫、炎症、心血管和感染等重大疾病领域具有广泛的治疗前景。 |
| Nanjing Chuangte | Established in 2019, the company is a clinical stage biotech developing innovative drugs for cancer and CV diseases. The company’s lead asset is in a phase3 clinical trial which is for the treatment of NSCLC. The target product is a potential best-in-class RET mutation inhibitor. |
| 南京创特 | 创特医药成立于2019年2月，是一家专门从事新药研发、技术转让、医药新产品产业化的创新型生物医药企业。聚焦肿瘤和脑血管系统疾病，致力于提供创新型的产品，通过创新驱动医药产业资源的整合，持续为患者健康服务，为客户创造价值。 |
| BJ Bioscience | Established in 2017, BJ Bioscience is a clinical stage biotech company incorporated in China.The mission is to discover and develop immune-oriented novel therapies for unmet medical needs with a focus on oncology, infectious and autoimmune diseases based the trade secrete protected antibody and unique bispecific antibody discovery platform. |
| 博际生物 | 博际生物医药成立于2017年，是一家处于临床阶段的生物技术公司，在中美都有实验室。公司立足于其独特的大分子包括双抗药物快速筛选平台，致力于研发拥有全球自主产权的、用于治疗免疫系统相关疾病的创新生物药，为全球的病人提供创新、高效的治疗手段。 |
| Xellsmart | Xellsmart is a new drug research and development company focusing on stem cell treatment. The company is committed to providing large-scale, low-cost stem cell therapies for a range of critical diseases, including Parkinson’s disease, for which there is no clinical solution. |
| 士泽生物 | 士泽生物是一家专注于干细胞治疗的新药研发公司。公司致力于为帕金森病等一系列尚无临床解决方案的重大疾病提供规模化、低成本的干细胞治疗方案。 |
| Alphamab Oncology | Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of innovative biotherapeutics for cancer treatment. With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, the company have built a robust pipeline in oncology and immunology with more than 20 phase II-III clinical trials running globally. |
| 康宁杰瑞 | 康宁杰瑞生物制药成立于2015年，专注于研发、生产和商业化创新肿瘤药物。2019年12月12日，康宁杰瑞生物制药在香港联交所主板上市，股票代码：9966.HK。 公司创建了具有自主知识产权的生物大分子药物发现、研发、生产技术平台，包括蛋白质/抗体工程平台、抗体筛选平台和多功能抗体开发平台。 基于先进的技术平台，康宁杰瑞开发出了丰富的产品管线，具有显著的差异化特点和强大的全球竞争力：其中1个产品KN035（恩沃利单抗注射液,全球首个皮下注射的PD-L1抑制剂；商品名：恩维达®）获批上市；2个产品入选国家“重大新药创制”专项；3个产品获美国FDA授予4项孤儿药资格；3个产品进入多项Ⅲ期或关键性临床研究。 |
| 爱思迈(Excelmab) | 爱思迈为一家专门从事肿瘤免疫双特异性抗体药物开发、生产、销售的创新型企业。公司依托团队已有完全自主知识产权的双特异性抗体研发平台ExMab®开发新型抗体药物。 |
| Increase Pharma | Increase Pharmal is a collection of research and development design, pilot incubation, achievement transformation in one of the new drug research and development institutions. The company has five major business sections, including TCM, chemical medicine innovation, clinical service, pilot-scale production and international business; it has set 15 R&D platform resources with process management system covering project approval, preclinical research, clinical research, industrialization and commercialization of scientific and research findings. |
| 盈科瑞 | 盈科瑞医药是一家集研发设计、中试孵化、成果转化于一体的新药研发机构。公司在国内下设多家子公司，业务包括中药版块、化药创新药版块、医学版块、中试生产和国际业务五大版块；建立了涵盖立项、临床前研究、临床研究及产业化等全链条研发体系。 |
| 博生吉(PersonGen) | 博生吉是一家全球临床阶段的生物制药公司，专注于开发领先的细胞疗法。公司目标是针对临床未满足需求的恶性肿瘤领域开发First-in-class和Best-in-class CAR-T细胞药物以造福肿瘤患者。 |
| 昂科免疫 | 昂科免疫由国际知名免疫学家刘阳教授创建，聚焦肿瘤和炎症性疾病的免疫治疗，目前拥有多个全球权益一类原创新药和大中华区独占许可引进的临床前及临床阶段产品。同OncoC4（原OncoImmune剥离CD24Fc后成立）持续合作开发，高效费比开发模式，同时Merck以4.25亿美元现金收购OncoImmune为昂科免疫持续带来巨大的现金收益。 |
| 唯思尔康（VesiCURE Therapeutics） | 唯思尔康公司是一家早期外泌体新药研发公司。唯思尔康构建国内首创的外泌体创新药研发平台，挖掘外泌体的医疗潜力，探索适应症突破口，重点在pre-clinical和clinical的实验验证，争取广泛的科研和医药合作，实现大规模工业化生产，推动外泌体医药产业链的建立和完善。 |
April 19 | Spring showcase 2022
BioToChina.org 